China SXT Pharmaceuticals Inc
NASDAQ:SXTC
Balance Sheet
Balance Sheet Decomposition
China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals Inc
Balance Sheet
China SXT Pharmaceuticals Inc
| Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
0
|
0
|
1
|
9
|
7
|
13
|
16
|
17
|
12
|
18
|
|
| Cash Equivalents |
0
|
0
|
1
|
9
|
7
|
13
|
16
|
17
|
12
|
18
|
|
| Total Receivables |
4
|
4
|
3
|
4
|
10
|
7
|
6
|
1
|
1
|
2
|
|
| Accounts Receivables |
2
|
3
|
3
|
4
|
4
|
5
|
3
|
1
|
1
|
1
|
|
| Other Receivables |
2
|
1
|
1
|
0
|
6
|
2
|
2
|
0
|
1
|
1
|
|
| Inventory |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Other Current Assets |
1
|
0
|
1
|
1
|
2
|
2
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
6
|
5
|
6
|
16
|
20
|
23
|
22
|
20
|
14
|
21
|
|
| PP&E Net |
0
|
0
|
1
|
2
|
2
|
2
|
2
|
1
|
1
|
0
|
|
| PP&E Gross |
0
|
0
|
1
|
2
|
2
|
2
|
2
|
1
|
1
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
1
|
1
|
1
|
1
|
2
|
2
|
3
|
3
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
9
|
9
|
9
|
8
|
0
|
|
| Total Assets |
6
N/A
|
5
-13%
|
8
+41%
|
17
+128%
|
22
+24%
|
35
+59%
|
34
-3%
|
30
-12%
|
23
-22%
|
22
-6%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
3
|
1
|
2
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
7
|
0
|
2
|
3
|
2
|
0
|
|
| Other Current Liabilities |
2
|
2
|
1
|
4
|
3
|
16
|
13
|
9
|
4
|
3
|
|
| Total Current Liabilities |
5
|
4
|
4
|
6
|
12
|
19
|
17
|
15
|
9
|
6
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
5
N/A
|
4
-34%
|
4
+22%
|
6
+46%
|
12
+93%
|
19
+51%
|
17
-8%
|
15
-13%
|
9
-38%
|
6
-32%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
4
|
45
|
|
| Retained Earnings |
1
|
0
|
2
|
3
|
7
|
10
|
16
|
22
|
25
|
28
|
|
| Additional Paid In Capital |
1
|
1
|
1
|
8
|
17
|
25
|
31
|
36
|
35
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
1
|
1
|
|
| Total Equity |
1
N/A
|
2
+150%
|
3
+78%
|
11
+238%
|
9
-15%
|
16
+70%
|
16
+3%
|
15
-11%
|
14
-5%
|
15
+11%
|
|
| Total Liabilities & Equity |
6
N/A
|
5
-13%
|
8
+41%
|
17
+128%
|
22
+24%
|
35
+59%
|
34
-3%
|
30
-12%
|
23
-22%
|
22
-6%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
14
|
|